EDITORIAL POLICY
EDITORIAL PRACTICE
All submissions are peer-reviwed before a decision on publication is reached. All manuscripts are considered to be confidential. Editor-in-Chief reads every manuscript received and assigns it’s a general priority level:
a) manuscript sent to reviewers immediately (double-blind peer review);
b) manuscript returned to authors with suggestions for modification and improvement;
c) rejected manuscripts.
Editor-in-Chief read the revised manuscript. Authors are welcome to suggest up to five potential reviewers for their manuscript, excluding co-authors or collaborators for the last three years, or to sk for the exclusion of reviewer(s) and the reasons for it. The Editor-in-Chief's decision is final.
Our review process is fast and ‘’submission to first decision’’ takes about six weeks. Each article receives a DOI (Digital Object Identifier) which is unique for every article published in the journal and is used for easier referencing and archiving.
Editors of Medicinski Glasnik will do their best to process all submissions as early as possible and publish accepted and edited items E-pub ahead of print. Full-text articles will be freely available to readers immediately upon online publication.
Medicinski Glasnik follows the updated recommendations of the International Committee of Medical Journal Editors (ICMJE) (http://icmje.org/icmje-recommendations.pdf) and adheres to publication ethics standards set by the Committee on Publication Ethics (COPE; http://publicationethics.org/resources) and the Council of Science Editors (CSE http://cseditors.wpengine.com/wp-content/uploads/entire_whitepaper.pdf).
Policy of trial registration
Since 2005, to promote the culture of transparency in research and reporting, publishing study protocols, and publishing negative results, and to promote trial registration, according to the ICMJE, a registration of trials in a public trials registry required as a condition of consideration for publication. The ICMJE expanded the definition of the types of trials that must be registered and adopted the World Health Organization’s (WHO) definition of clinical trial (3): “any research study that prospectively assigns human participants or groups of humans to one or more health‐related interventions to evaluate the effects on health outcomes” (http://www.who.int/ictrp/en/). The ICMJE implemented the WHO definition of clinical trials for all trials that begin enrollment on or after 1 July 2008. In addition to accepting registration in any of the 5 existing registries, the ICMJE will accept registration of clinical trials in any of the primary registers that participate in the WHO International Clinical Trials Registry Platform (http://www.who.int/ictrp/network/primary/en/index.html).
Registration in a partner register only is insufficient. In each register authors can find guidelines for registration process. After successful registration, authors will obtain a registration number, which should be included (with the name of registration database) at the end of article’s Abstract.
The revised Declaration of Helsinki (https://www.wma.net/policies‐post/wma‐declaration‐ofhelsinki‐ethical‐principles‐for‐medical‐research‐involving‐human‐subjects/ ) elaborates in two items the registration in publicly available databases and ethical obligations to publish or otherwise make publicly available negative and inconclusive, as well as positive results. Item 19 requires: “Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject“ and item 30 states: “Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports.
They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available.
To properly report different types of research studies, authors are advised to consult the statements of the EQUATOR network at: http://www.equator-network.org/
Finally, editors of Medicinski Glasnik endorse the principles of the integrity, transparency and quality of pre- and post-publication communications set by the Sarajevo Declaration on Integrity and Visibility of Scholarly Publications (http://www.cmj.hr/2016/57/6/28051276.htm).
Our review process from submission to first decision takes approximately six weeks.
Each published item receives a DOI (Digital Object Identifier) which is unique for every article published in the journal and is used for easier referencing and archiving.
Plagiarism detection and retractions
Editors check all accepted manuscripts for texts and graphics plagiarism. In some cases, authors may be asked to provide a disclaimer that their reports are free of any research misconduct. In all suspected cases, the editors act in accordance with the COPE flowcharts: http://publicationethics.org/resources/flowcharts. Plagiarized or otherwise unethical and erroneous published items will be retracted in accordance with the COPE retraction guidelines: http://publicationethics.org/files/retraction%20guidelines_0.pdf
Conflicts of interest
All authors, reviewers and editors are responsible for disclosure of any financial and non-financial conflicts of interest that may compromise the trustworthiness of their reports. It is therefore recommended to familiarize with the ICMJE statements and fill related conflicts disclosure form: http://icmje.org/conflicts-of-interest/ and send us by e-mail along with Authorship Statement.
Research ethics considerations